Clinical biomarker–based biological ageing and the risk of adverse outcomes in patients with chronic kidney disease

In patients with CKD, both KDM-BA acceleration and PhenoAge acceleration were associated with an increased risk of ESKD, CVD and all-cause mortality, and KDM-BA or PhenoAge may be a better predictor on adverse outcomes than LTL.